BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• Biotech Bay

  ScandiDos Announces Delta4 Discover™ Launch Plans At ASTRO Meeting

  September 17, 2014

   · 

  1 min read
• Drug Development

  Oncolytics Biotech Inc. Announces Overall And KRAS-Mutated Patient Data From U.S. Randomized Phase 2 Pancreatic Cancer Study

  September 17, 2014

   · 

  7 min read
• BioMidwest

  Aastrom Biosciences, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

  September 17, 2014

   · 

  4 min read
• Roche To Present Latest Oncology Advances During ESMO 2014 Congress

  September 17, 2014

   · 

  5 min read
• FUJIFILM Visualsonics Unveils The Ultimate Pre-Clinical Imaging Experience With The Vevo® 3100 At The World Molecular Imaging Congress Annual Meeting

  September 17, 2014

   · 

  1 min read
• Policy

  Eagle Pharmaceuticals Announces That Teva Pharmaceutical Industries Limited Requests A Motion To Dismiss With Prejudice In Its Bendamustine Patent Infringement Lawsuit

  September 17, 2014

   · 

  1 min read
• Business

  Enumeral Biomedical Awarded Phase II SBIR Contract From The National Cancer Institute To Advance Human Tissue Immuno-Oncology Profiling

  September 17, 2014

   · 

  1 min read
• Lone Star Bio

  Asuragen, Inc.’s Xpansion Interpreter® Test Study Of 1,040 Transmissions Of Fragile X Alleles Reveals Personalized Risks For Expansion From Parent To Child

  September 17, 2014

   · 

  1 min read
• Drug Development

  Janssen-Cilag International NV Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type

  September 17, 2014

   · 

  1 min read
• Drug Development

  Janssen-Cilag International NV Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adu

  September 17, 2014

   · 

  1 min read